Special Issue

Personalized Medicine Approaches to Depression Prevention, Diagnosis, and Therapeutics

Message from the Guest Editor

The use of modern "omics" technologies permits more accurate medical diagnosis and tailored therapeutics. Major depressive disorder (MDD) is remarkably common, yet is often resistant to effective treatment because of its diverse presentation and complex pathogenesis, defined by both genetic and environmental factors. Recent developments on the neurobiological basis of MDD suggest that a number of novel genetic loci may be associated with MDD and related conditions. Promising work suggests that a better understanding of the risk profiles, symptom-based phenotypes, and genetics could be used to improve prevention, identification, and treatment. At the same time, depression is a profoundly human experience, and translating precision medicine approaches into effective personalized medicine must incorporate individual nuances and therapeutic relationships. This Special Issue of the *Journal of Personalized Medicine* is focused on describing the current state of personalized medicine approaches to MDD, as well as the promise of modern "omics" technologies in its prevention, detection, and treatment.

Deadline for manuscript submissions

closed (20 February 2022)

About the Journal

Message from the Editor-in-Chief

Journal of Personalized Medicine (*JPM*; ISSN 2075-4426) is an international, open access journal aimed at bringing all aspects of personalized medicine to one platform. *JPM* publishes cutting edge, innovative preclinical and translational scientific research and technologies related to personalized medicine (e.g., precision medicine, pharmacogenomics/proteomics, systems biology, 'omics association analysis). *JPM* is covered in Scopus, the Science Citation Index Expanded (SCIE), PubMed, PMC, Embase, and other databases.

Editor-in-Chief

Prof. Dr. David Alan Rizzieri
1. Novant Health Cancer Institute, Winston-Salem, NC 27103, USA
2. Division of Hematologic Malignancies and Cellular Therapy, Duke University, Durham, NC 27710, USA

Author Benefits

High Visibility:
indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, and other databases.

Journal Rank:
JCR - Q1 (Medicine, General and Internal) / CiteScore - Q2 (Medicine (miscellaneous))

Rapid Publication:
manuscripts are peer-reviewed and a first decision is provided to authors approximately 16.7 days after submission; acceptance to publication is undertaken in 2.5 days (median values for papers published in this journal in the first half of 2024).